Literature DB >> 9774490

Effects of cardio-pulmonary bypass on vancomycin plasma concentration decay.

P A Miglioli1, F Merlo, E Grabocka, R Padrini.   

Abstract

The objective of the study was to investigate possible changes in vancomycin serum levels induced by cardio-pulmonary bypass (CPB). Ten cardiac patients (seven males, three females, aged between 56 and 81), who underwent cardiac surgery requiring CPB, took part in the study. Vancomycin (15 mg kg-1) was intravenously infused over 60 min before anaesthesia and blood samples were taken at appropriate times after drug administration (0, 0.5, 1, 6, 8 h), after starting CPB (0, 5, 30 and 60 min) and after aortic unclamping (0, 5, 30, 60, 120 min). Drug serum concentrations were determined by means of a fluorescence polarization immunoassay. The area under the concentration-time curve (AUC) measured during CPB were compared with the AUC extrapolated in the same interval by fitting a two-compartment pharmacokinetic model to drug concentrations obtained before and after CPB. Five minutes after starting CPB vancomycin serum levels decreased, on average, by 40.9% and remained steadily lower than the expected values over the next 60 min. In the same interval, the measured AUC was 31.7% lower than the expected AUC. In no instance did serum levels fall below the MIC for most common pathogens (1-2 mg l-1). At aortic unclamping serum levels slightly rebounded but tended to remain lower than the expected concentrations over the next 120 min. In conclusion, during CPB vancomycin serum levels invariably decreased but, at the dose employed (15 mg kg-1), remained in a potentially effective range for antimicrobial prophylaxis. Copyright 1998 The Italian Pharmacological Society

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774490     DOI: 10.1006/phrs.1998.0370

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  4 in total

Review 1.  Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients.

Authors:  Federico Pea; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

2.  Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.

Authors:  Megan H Nguyen; Samantha J Eells; Jennifer Tan; Corinne T Sheth; Bassam Omari; Margarita Flores; Jeffrey Wang; Loren G Miller
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

3.  Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens.

Authors:  Saeed A Alqahtani; Abdullah S Alsultan; Hussain M Alqattan; Ahmed Eldemerdash; Turki B Albacker
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

4.  Incidence and risk factors for potentially suboptimal serum concentrations of vancomycin during cardiac surgery.

Authors:  Paolo Cotogni; Cristina Barbero; Mauro Rinaldi
Journal:  World J Cardiol       Date:  2018-11-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.